Klaus Überla to Antibodies, Viral
This is a "connection" page, showing publications Klaus Überla has written about Antibodies, Viral.
Connection Strength
0.171
-
Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020. Viruses. 2021 06 10; 13(6).
Score: 0.090
-
Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus. PLoS One. 2012; 7(5):e38068.
Score: 0.024
-
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Eur J Immunol. 2021 10; 51(10):2478-2484.
Score: 0.023
-
Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2021 Apr; 40(4):751-759.
Score: 0.022
-
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020 07 24; 11(1):3774.
Score: 0.005
-
Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology. 2007 May 25; 362(1):26-37.
Score: 0.004
-
S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol. 2004 Jun; 78(12):6134-42.
Score: 0.003